QualityStocks would like to highlight Cellceutix Corporation (OTCBB: CTIX), a clinical stage biopharmaceutical company focused on the development of a pipeline of small molecule drugs to treat unmet medical conditions, including cancers and autoimmune diseases. The company’s flagship compound, Kevetrin, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers that have proven resistant to current cancer therapies.
In the company’s news yesterday,
Cellceutix reported that it has been advised that the clinical trials for its novel anti-cancer drug candidate, Kevetrin, will be going active this week. The trials are being conducted at Harvard Cancer Centers Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Both centers are ready to begin the recruitment, enrollment, and dosing processes.
The clinical trial is titled “A phase1, open-label, dose-escalation, safety, pharmacokinetic and pharmacodynamic study of Kevetrin (Thioureidobutyronitrile) administered intravenously, in patients with advanced solid tumors.” Cellceutix has been advised to expect the first dosing of Kevetrin to be administered within approximately one week of activating the trial.
In more than 50% of all human cancers, p53 is limited in its anti-tumor activities by mutations in the protein itself. Currently, there are more than 10 million people with tumors that have inactivated p53 and a similar number have p53 pathways that are partially abrogated. This has left cancer researchers with the task of searching for therapies that could restore the protein’s protective function. Kevetrin appears to do so most of the time.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.